

Peer Tfelt-Hansen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403996/publications.pdf>

Version: 2024-02-01

112
papers

4,088
citations

196777

29
h-index

134545

62
g-index

119
all docs

119
docs citations

119
times ranked

2995
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological strategies to treat attacks of episodic migraine in adults. Expert Opinion on Pharmacotherapy, 2021, 22, 305-316.	0.9	11
2	Onset of action in placebo-controlled migraine attacks trials: A literature review and recommendation. Cephalalgia, 2021, 41, 148-155.	1.8	4
3	Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study. Cephalalgia, 2021, 41, 1262-1267.	1.8	3
4	Critique of the analysis of the time course for the antimigraine effect of ubrogepant 50 mg. Clinical relevance versus statistical significance. Cephalalgia, 2021, 41, 033310242110146.	1.8	1
5	Can tendon reflexes be elicited by both stretch and vibration in man?. Brain and Behavior, 2021, 11, e02191.	1.0	1
6	Naratriptan is as effective as sumatriptan for the treatment of migraine attacks when used properly. A mini-review. Cephalalgia, 2021, 41, 1499-1505.	1.8	5
7	Doubtful use of placebo following placebo in recent controlled trials of lasmiditan and ubrogepant for the treatment of migraine attacks. Cephalalgia, 2021, , 033310242110299.	1.8	0
8	Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review. Cephalalgia, 2020, 40, 122-126.	1.8	7
9	Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks. Cephalalgia, 2020, 40, 1331-1335.	1.8	3
10	Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor. Neurological Research and Practice, 2020, 2, 11.	1.0	35
11	Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect. British Journal of Clinical Pharmacology, 2019, 85, 2487-2498.	1.1	6
12	Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacology Research and Perspectives, 2019, 7, e00496.	1.1	28
13	Misused and Misleading: "100% Response Rate" to Galcanezumab in Patients With Episodic Migraine. Headache, 2019, 59, 626-626.	1.8	2
14	Further Questioning of the Significance of the Gepants: A Response. Headache, 2019, 59, 1831-1831.	1.8	0
15	The Emperor's New Gepants: Are the Effects of the New Oral CGRP Antagonists Clinically Meaningful?. Headache, 2019, 59, 113-117.	1.8	45
16	Evaluating the reporting of adverse events in controlled clinical trials conducted in 2010-2015 on migraine drug treatments. Cephalalgia, 2018, 38, 1885-1895.	1.8	1
17	Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine. CNS Drugs, 2017, 31, 389-403.	2.7	8
18	Meralgia Paresthetica after Prone Positioning Ventilation in the Intensive Care Unit. Case Reports in Critical Care, 2016, 2016, 1-3.	0.2	17

#	ARTICLE	IF	CITATIONS
19	The Evidence for Prescription Information for Possible Use of a Repeated Dose of Oral Triptans: A Comment. <i>Headache</i> , 2016, 56, 878-882.	1.8	2
20	General lack of use of placebo in prophylactic, randomised, controlled trials in adult migraine. A systematic review. <i>Cephalalgia</i> , 2016, 36, 960-969.	1.8	11
21	Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations. <i>Headache</i> , 2016, 56, 1482-1491.	1.8	4
22	The putative P-gp inhibitor telmisartan does not affect the transcellular permeability and cellular uptake of the calcium channel antagonist verapamil in the P-glycoprotein expressing cell line MDCK II MDR1. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00151.	1.1	5
23	Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT _{1F} agonists and CGRP antagonists. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1409-1418.	1.5	16
24	Reporting withdrawals due to adverse events in single-attack acute migraine clinical trials. <i>Cephalalgia</i> , 2015, 35, 366-367.	1.8	1
25	What efficacy measures are clinically relevant and should be used in Cochrane Reviews of acute migraine trials? A viewpoint. <i>Cephalalgia</i> , 2015, 35, 457-459.	1.8	3
26	The Qualitative Problem of Major Quotation Errors, as Illustrated by 10 Different Examples in the Headache Literature. <i>Headache</i> , 2015, 55, 419-426.	1.8	2
27	Site of effect of LY2951742 for migraine prophylaxis. <i>Lancet Neurology</i> , The, 2015, 14, 31-32.	4.9	9
28	The Importance of Some Possible Somatic and Environmental Risk Factors for the Development of Migraine. <i>Journal of Neurology Research</i> , 2015, 5, 193-198.	0.2	0
29	Why Is Guanfacine Recommended by AHS and ANN for Migraine Prevention?. <i>Headache</i> , 2014, 54, 754-755.	1.8	0
30	Imprecise diagnosis of migraine with aura in the Women's Health Study. Does it matter?. <i>Cephalalgia</i> , 2014, 34, 559-559.	1.8	0
31	Parenteral Treatment of Episodic Tension-Type Headache. Is There Sufficient Evidence?. <i>Headache</i> , 2014, 54, 922-923.	1.8	0
32	Is Orally Inhaled Dihydroergotamine (DHE) Equivalent in Efficacy in Migraine to Intravenous DHE?. <i>Headache</i> , 2014, 54, 383-383.	1.8	2
33	Animal Migraine Models for Drug Development: Status and Future Perspectives. <i>CNS Drugs</i> , 2013, 27, 1049-1068.	2.7	26
34	The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: A randomized, double-blind, placebo-controlled cross-over study. <i>Scandinavian Journal of Pain</i> , 2013, 4, 48-52.	0.5	23
35	Sumatriptan: a review of its pharmacokinetics, pharmacodynamics and efficacy in the acute treatment of migraine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 91-103.	1.5	27
36	Vertebral Artery Dissection Associated with Generalized Convulsive Seizures: A Case Report. <i>Case Reports in Neurology</i> , 2013, 5, 125-129.	0.3	5

#	ARTICLE	IF	CITATIONS
37	Clinical Pharmacology of Current and Future Drugs for the Acute Treatment of Migraine: A Review and An Update. <i>Current Clinical Pharmacology</i> , 2012, 7, 66-72.	0.2	5
38	Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. <i>Cephalalgia</i> , 2012, 32, 6-38.	1.8	326
39	Taking the Negative View of Current Migraine Treatments. <i>CNS Drugs</i> , 2012, 26, 375-382.	2.7	63
40	Pain Freedom at 2 Hours in Migraine after Telcagepant 300mg. <i>CNS Drugs</i> , 2011, 25, 269-270.	2.7	2
41	Excellent Tolerability But Relatively Low Initial Clinical Efficacy of Telcagepant in Migraine. <i>Headache</i> , 2011, 51, 118-123.	1.8	30
42	Optimal balance of efficacy and tolerability of oral triptans and telcagepant: a review and a clinical comment. <i>Journal of Headache and Pain</i> , 2011, 12, 275-280.	2.5	14
43	Subcutaneous sumatriptan: results of a peculiar, unpublished, comparative, double-blind, randomised, and controlled trial. <i>Journal of Headache and Pain</i> , 2011, 12, 269-270.	2.5	1
44	Association between migraine, lifestyle and socioeconomic factors: a population-based cross-sectional study. <i>Journal of Headache and Pain</i> , 2011, 12, 157-172.	2.5	108
45	Suggested randomised, controlled trial with frovatriptan. <i>Journal of Headache and Pain</i> , 2011, 12, 665-666.	2.5	1
46	Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. <i>Cephalalgia</i> , 2011, 31, 683-690.	1.8	29
47	Co-morbidity of migraine with somatic disease in a large population-based study. <i>Cephalalgia</i> , 2011, 31, 43-64.	1.8	105
48	Possible site of action of CGRP antagonists in migraine. <i>Cephalalgia</i> , 2011, 31, 748-750.	1.8	52
49	Is sustained pain freedom and no adverse events a clinically relevant endpoint in acute migraine treatment?. <i>Cephalalgia</i> , 2011, 31, 1240-1240.	1.8	2
50	Early Responses in Randomized Clinical Trials of Triptans in Acute Migraine Treatment. Are They Clinically Relevant? A Comment. <i>Headache</i> , 2010, 50, 1198-1200.	1.8	5
51	No effect of pure oxygen inhalation on headache induced by glyceryl trinitrate. <i>Journal of Headache and Pain</i> , 2010, 11, 93-95.	2.5	3
52	Are the current IHS guidelines for migraine drug trials being followed?. <i>Journal of Headache and Pain</i> , 2010, 11, 457-468.	2.5	14
53	Extracranial source of increased CGRP in migraine children?. <i>Cephalalgia</i> , 2010, 30, 380-381.	1.8	0
54	Licence for Botox in so-called chronic migraine. <i>Lancet</i> , The, 2010, 376, 1825-1826.	6.3	13

#	ARTICLE	IF	CITATIONS
55	CHLORMEZANONE IN THE TREATMENT OF MIGRAINE ATTACKS. A DOUBLE BLIND COMPARISON WITH DIAZEPAM AND PLACEBO.. Acta Neurologica Scandinavica, 2009, 65, 81-82.	1.0	0
56	Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurology, The, 2009, 8, 679-690.	4.9	458
57	Calcitonin gene-related peptide in blood: is it increased in the external jugular vein during migraine and cluster headache? A review. Journal of Headache and Pain, 2009, 10, 137-143.	2.5	52
58	What can be learned from the history of recurrence in migraine? A comment. Journal of Headache and Pain, 2009, 10, 311-315.	2.5	8
59	Assymetry of Temporal Artery Diameters During Spontaneous Attacks of Cluster Headache. Headache, 2009, 49, 383-385.	1.8	4
60	Verapamil for Cluster Headache. Clinical Pharmacology and Possible Mode of Action. Headache, 2009, 49, 117-125.	1.8	63
61	Cluster Headache and Aura. Headache, 2009, 49, 786-787.	1.8	4
62	Pharmacogenomics and migraine: possible implications. Journal of Headache and Pain, 2008, 9, 13-18.	2.5	13
63	Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate. Journal of Headache and Pain, 2008, 9, 215-220.	2.5	16
64	Triptans vs Other Drugs for Acute Migraine. Are There Differences in Efficacy? A Comment. Headache, 2008, 48, 601-605.	1.8	39
65	Frovatriptan and Data Publication. Headache, 2008, 48, 1382-1383.	1.8	8
66	Acute migraine therapy: recent evidence from randomized comparative trials. Current Opinion in Neurology, 2008, 21, 331-337.	1.8	29
67	Over-the-Counter Triptans for Migraine. CNS Drugs, 2007, 21, 877-883.	2.7	36
68	Predictors of Migraine Headache Recurrence: A Pooled Analysis From the Eletriptan Database. Headache, 2007, 48, 070629211050002-???.	1.8	30
69	Contractile responses to ergotamine and dihydroergotamine in the perfused middle cerebral artery of rat. Journal of Headache and Pain, 2007, 8, 83-89.	2.5	7
70	Acute pharmacotherapy of migraine, tension-type headache, and cluster headache. Journal of Headache and Pain, 2007, 8, 127-134.	2.5	12
71	Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. A comment. Journal of Headache and Pain, 2007, 8, 273-276.	2.5	26
72	Increasing the effect of triptans in migraine. Lancet, The, 2006, 368, 1313-1314.	6.3	4

#	ARTICLE	IF	CITATIONS
73	Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial. <i>Headache</i> , 2006, 46, 264-275.	1.8	32
74	Understanding clinical trials in migraine. <i>Journal of Headache and Pain</i> , 2006, 7, 101-108.	2.5	6
75	Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study. <i>Journal of Headache and Pain</i> , 2006, 7, 389-394.	2.5	11
76	Methodological Issues in Systematic Reviews of Headache Trials: Adapting Historical Diagnostic Classifications and Outcome Measures to Present Day Standards. <i>Headache</i> , 2005, 45, 459-465.	1.8	23
77	To Members of the International Headache Society (IHS). <i>Cephalalgia</i> , 2004, 24, 691-693.	1.8	22
78	The Phosphodiesterase 3 Inhibitor Cilostazol Dilates Large Cerebral Arteries in Humans without Affecting Regional Cerebral Blood Flow. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2004, 24, 1352-1358.	2.4	66
79	Topiramate in migraine prophylaxis. <i>Journal of Neurology</i> , 2004, 251, 943-50.	1.8	288
80	The Truth About Frovatriptan. <i>Headache</i> , 2003, 43, 699-700.	1.8	3
81	Endothelium-Dependent Relaxant Responses to Selective 5-HT _{1B/1D} Receptor Agonists in the Isolated Middle Cerebral Artery of the Rat. <i>Journal of Vascular Research</i> , 2003, 40, 561-566.	0.6	25
82	The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects. <i>British Journal of Clinical Pharmacology</i> , 2002, 54, 38-44.	1.1	6
83	Success and failure of triptans. <i>Journal of Headache and Pain</i> , 2001, 2, 3-11.	2.5	9
84	Reply to O'Quinn et al. <i>Headache</i> , 2000, 40, 608-609.	1.8	2
85	A Comment on Time-to-Event Analysis for Headache Relief. <i>Cephalalgia</i> , 2000, 20, 255-256.	1.8	6
86	Triptans in Migraine. <i>Drugs</i> , 2000, 60, 1259-1287.	4.9	442
87	Oral Rizatriptan Versus Oral Sumatriptan: A Direct Comparative Study in the Acute Treatment of Migraine. <i>Headache</i> , 1998, 38, 748-755.	1.8	192
88	PROPHYLACTIC PHARMACOTHERAPY OF MIGRAINE. <i>Neurologic Clinics</i> , 1997, 15, 153-165.	0.8	19
89	Drug treatment of migraine. <i>Current Opinion in Neurology</i> , 1996, 9, 211-213.	1.8	11
90	Migraine – Diagnosis and Pathophysiology. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1994, 75, 72-75.	0.0	7

#	ARTICLE	IF	CITATIONS
91	Sumatriptan for the Treatment of Migraine Attacks-A Review of Controlled Clinical Trials. Cephalalgia, 1993, 13, 238-244.	1.8	75
92	Small arteries can be accurately studied in vivo, using high frequency ultrasound. Ultrasound in Medicine and Biology, 1993, 19, 717-725.	0.7	34
93	Initial Study of the Peripheral Vascular Effects of a Combination of Sumatriptan and Ergotamine in Man. Cephalalgia, 1991, 11, 230-231.	1.8	2
94	Determination of the luminal diameter of the radial artery in man by high frequency ultrasound: A methodological study. Ultrasound in Medicine and Biology, 1990, 16, 787-791.	0.7	31
95	Tachyphylaxis to the Local Effect of 5HT, Infused into a Peripheral Vein. Cephalalgia, 1989, 9, 88-89.	1.8	1
96	Dermascan A, A High Frequency Acoustic Scanner for Non-Invasive Studies of the Luminal Diameter of Superficially Situated, Medium-Sized Arteries. Cephalalgia, 1989, 9, 72-73.	1.8	0
97	Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain, 1989, 38, 17-24.	2.0	340
98	Headache and Changes in the Diameter of the Radial Artery during 7 Hours Intravenous Nitroglycerin Infusion. Cephalalgia, 1989, 9, 82-83.	1.8	2
99	Efficacy of β -Blockers in Migraine. Cephalalgia, 1986, 6, 15-24.	1.8	73
100	Clinical Trial of Nimodipine for Single Attacks of Classic Migraine. Cephalalgia, 1985, 5, 125-131.	1.8	29
101	Intramuscular ergotamine: Plasma levels and dynamic activity. Clinical Pharmacology and Therapeutics, 1985, 37, 29-35.	2.3	56
102	Methodological Aspects of Drug Trials in Migraine. pp 216-226. Neuroepidemiology, 1985, 4, 216-226.	1.1	0
103	Effervescent Metoclopramide and Aspirin (Migravess) Versus Effervescent Aspirin or Placebo for Migraine Attacks: A Double-Blind Study. Cephalalgia, 1984, 4, 107-111.	1.8	82
104	Dose-response Curve for the Ergotamine-induced Decrease of Peripheral Systolic Blood Pressure in Man. Acta Pharmacologica Et Toxicologica, 1984, 55, 238-241.	0.0	7
105	Action of some pericranial muscles during provoked attacks of common migraine. Pain, 1982, 14, 121-135.	2.0	18
106	Spreading Cerebral Oligemia in Classical- and Normal Cerebral Blood Flow in Common Migraine. Headache, 1982, 22, 242-248.	1.8	113
107	Chlormezanone in the Treatment of Migraine Attacks: A Double Blind Comparison with Diazepam and Placebo. Cephalalgia, 1982, 2, 205-210.	1.8	6
108	Mechanism of Ergotamine-induced Decrease of Peripheral Systolic Blood Pressure in Man. Acta Pharmacologica Et Toxicologica, 1982, 51, 122-125.	0.0	2

#	ARTICLE	IF	CITATIONS
109	Methodological Aspects of Prophylactic Drug Trials in Migraine. <i>Cephalalgia</i> , 1981, 1, 127-141.	1.8	73
110	Arterial Response to Ergotamine Tartrate in Abusing and Non-abusing Migraine Patients. <i>Acta Pharmacologica Et Toxicologica</i> , 1981, 48, 69-72.	0.0	10
111	Paracetamol (Acetaminophen) versus Acetylsalicylic Acid in Migraine. <i>European Neurology</i> , 1980, 19, 163-165.	0.6	28
112	The Effect of Single Dose Ergotamine Tartrate on Peripheral Arteries in Migraine Patients: Methodological Aspects and Time Effect Curve. <i>Acta Pharmacologica Et Toxicologica</i> , 1980, 47, 151-156.	0.0	38